Autoimmune polyglandular syndrome type 1: a case report and brief review

Ifeanyi Nwosua, Oreoluwa Oladiranb, Chinyere Ogbonna-Nwosuc, and Anulika Anyatad

1. Introduction

Autoimmune polyglandular syndrome (APS) type 1, also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dysplasia-candidiasis (APECED) [1] or Whitaker syndrome [2], is defined as the presence of two or more of the following: Addison’s disease, chronic mucocutaneous candidiasis, and hypoparathyroidism [3]. It occurs in childhood with 1:1 male to female ratio, inherited in an autosomal recessive pattern, and has an incidence of about 3/1,000,000 people. Although treatment is identical whether it occurs in isolation or as part of an APS, clinicians must be alert to syndromic associations of autoimmune diseases to prevent delayed diagnosis.

2. Case report

A 29-year-old man with past medical history of Addison’s disease and hypothyroidism who recently relocated to the USA from Puerto Rico presented to the emergency department (ED) with chief complaints of fatigue, palpitations, and light headedness. He was previously maintained on twice daily hydrocortisone and daily levothyroxine supplementation but had been off his medications for 5 days. He denied chest pain or shortness of breath. He also denied tremors, easy fatigability, weight gain, hoarseness of voice, or changes in bowel habit. Of note, he reported a childhood history of recurrent seizures due to hypocalcemia and had since been on calcium and vitamin D supplementation. He had no family history of autoimmune disease and review of systems was otherwise unremarkable. His knowledge about his medical condition was limited.

On physical examination, he was in no acute distress. He was hypotensive with BP 89/67 and tachycardic with pulse rate of 115 bpm. Other vital signs were normal. Chvostek sign was negative and there was no thyromegaly on neck palpation. Oral examination showed multiple hyperpigmented lesions on the dorsum of his tongue (Figure 1) and multiple deformed and pitting finger nails in both hands (Figure 2). The remainder of the physical examination was unremarkable.

Basic metabolic panel revealed hyponatremia with Na 129 meq/L (136–145) and potassium of 4.8 meq/L (3.5–5.1). He was also severely hypocalcemia with ionized calcium of 0.96 mmol/L (1.15–1.33). Fasting blood glucose was normal. Thyroid function test showed elevated thyrotropin level at 5.807 uIU/mL (0.450–5.330) with normal free thyroxine level at 0.94 ng/dL (0.58–1.64). AM cortisol was markedly reduced at <1 mcg/dL (6.7–22.6). ACTH was markedly elevated at 390 pg/mL (12–88). Parathyroid hormone was markedly reduced at <6 pg/mL (12–88). Complete blood count was normal, as was coagulation profile.

ECG also showed sinus tachycardia with no ischemic changes.

The patient was given intravenous saline and doubled his normal dose of his steroids. His levothyroxine dose was continued at 75 mcg daily while intravenous fluid was administered. He was admitted to the hospital for further diagnostic workup and was discharged on the next day with scheduled follow-up appointments.

3. Discussion

APS type 1 is an autoimmune syndrome that involves the multiple endocrinopathies and mucocutaneous candidiasis. Its manifestation starts early in life with the cardinal clinical disorders being one of mucocutaneous candidiasis, Addison’s disease, and hypoparathyroidism. Recognizing the syndromic nature of one autoimmune disease will facilitate an active search for other conditions which would allow early detection, management, follow-up, and most importantly patient education and counselling to avoid potential complications. We present the case of a young immigrant with multiple endocrinopathies and mucocutaneous candidiasis who presented with features of adrenal insufficiency. Our aim was to briefly review APS type 1 as a disease entity and to highlight the importance of patient education in its management.
and oral calcium were given to correct hypocalcemia. His symptoms gradually improved, and he was discharged home on hydrocortisone 20 mg in the morning and 10 mg at night with fludrocortisone 0.1 mg daily and levothyroxine 75 mcg daily.

On follow-up in clinic 2 weeks later, patient was noted to be doing well. Patient education regarding medication adherence and stress dosing to avoid potentially life-threatening adrenal crisis and the importance of medic alert bracelets was reinforced. The patient was classified as having APS type 1 because of the presence of hypoparathyroidism, Addison’s disease, and chronic mucocutaneous candidiasis, and promptly referred to the endocrinologist for continuity of care (Figure 3).

3. Discussion

APS type 1 occurs due to loss of function of the autoimmune regulator gene – AIRE (AI – autoimmune, RE – regulator) gene, located on chromosome 21 particularly expressed in the thymus gland which plays an important role in immune regulation by distinguishing self from non-self. The result is the formation of autoantibodies directed against specific tissue [4–6].

APS type 1 is almost always inherited as autosomal recessive with both set of AIRE genes affected, although cases of autosomal dominant mutation in AIRE have been described [5] and the disease spectrum is much more narrow than in the recessive type [6].

Other less frequent autoimmune diseases occurring in association with this condition include type 1 diabetes mellitus, vitiligo, pernicious anemia, primary hypothyroidism, hypergonadotropic hypogonadism (primary hypogonadism), pituitary failure, autoimmune hepatitis, alopecia, interstitial nephritis, malabsorption syndrome, splenic aplasia or hypoplasia, and pure red cell aplasia [5,7].

Onset typically begins in childhood with multiple autoimmune disorders manifesting throughout patient’s lifetime [8]. In most cases, the first symptom is a chronic mucocutaneous candidiasis even before the development of endocrine disorders and usually affects the oral cavity, esophagus, and the skin. It is the most common manifestation of APS type 1 and is seen in almost 100% of cases [5].

The cause of mucocutaneous candidiasis in these patients, a hallmark of the disease, was initially unknown and not attributed to autoimmune dysfunction [4]. More recent studies found that the disruption of the T helper-17 cell (Th-17)-based adaptive immunity to fungal infection is responsible for the chronic mucocutaneous candidiasis (CMC) [9]. Patients with APS type 1 produce autoantibodies against specific Th-17 cells cytokines mainly IL17A, IL-17F, and IL-22 thus disrupting the innate antifungal immunity [9,10].
Hypoparathyroidism is usually the first endocrine disorder to manifest during the course of the disease and has been reported in about 70–93% of cases. Addison’s disease has a prevalence of about 60–100% [5]. Timing of the major clinical features is illustrated in the table below. Other clinical presentations may include fatigue due to pernicious anemia, enamel hypoplasia, dystrophic nails, diarrhea, and cholelithiasis from malabsorption syndrome, and abnormal liver enzymes in autoimmune hepatitis [11]. Apart from the more common cutaneous associations, a rare case of acquired generalized lipodystrophy has been associated with APS type1 [12].

Diagnosis of APS type 1 is largely based on the measurement of serum endocrine and organ-specific autoantibody in patients presenting with clinical history suggestive of one or more endocrine disorder and (or) chronic mucocutaneous candidiasis. A definitive diagnosis can be made through DNA analysis for AIRE gene mutation [13], and this may be of benefit in patients who do not meet the diagnostic criteria of APS type 1 at initial presentation [14]. The finding of one organ-specific autoimmune disorder should prompt further evaluation for other associations.

The mainstay of treatment remains hormone replacement and systemic antifungal therapy. Correction of deficient electrolytes such as calcium and sodium may be required. Immunosuppressive therapy has been used with variable success rates. Routine monitoring and investigation of patients with autoimmune disorder should prompt further evaluation for other associations.

The mainstay of treatment remains hormone replacement and systemic antifungal therapy. Correction of deficient electrolytes such as calcium and sodium may be required. Immunosuppressive therapy has been used with variable success rates. Routine monitoring and investigation of patients with autoimmune disorder should prompt further evaluation for other associations.

4. Conclusion

In summary, this case highlights the need for high index of suspicion for APS and judicious search for other autoimmune conditions whenever one organ-specific autoimmune disorder is diagnosed. Long-term monitoring of patients with autoimmune disorders is important because the time interval before the appearance of other endocrine disorders cannot be predicted. Given how common chronic mucocutaneous candidiasis is as well as its early manifestation, routine evaluation is advised to detect any oral or esophageal squamous cell carcinoma (SCC) increases.

Disclosure statement

No potential conflict of interest was reported by the authors.

ORCID

Chinyere Oghbonna-Nwosu http://orcid.org/0000-0002-7990-3549

References

[1] Ahonen P, Myllärniemi S, Sipilä I, et al. Clinical variation of autoimmune polyendocrinopathy–candidiasis–ectodermal Dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;322:1829–1836.
[2] Whitaker J, Landing BH, Esselborn VM, et al. The syndrome of familial juvenile hypoadrenocorticism, hypoparathyroidism and superficial moniliasis. J Clin Endocrinol Metab. 1956;16:1374–1387.
[3] Betterle C, Greggio NA, Volpato M. Clinical review 93: autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab. 1998;83:1049–1055.
[4] Kämpe O. Introduction: autoimmune polyendocrine syndrome type 1 (APS-1): a rare monogenic disorder as a model to improve understanding of tolerance and autoimmunity: symposium. J Intern Med. 2009;265:511–513.
[5] Weiler FG, Dias-da-Silva MR, Lazaretti-Castro M. Autoimmune polyendocrine syndrome type 1: case report and review of literature. Arq Bras Endocrinol Metabol. 2012;56:54–66.
[6] Anderson MS, Su MA. AIRE expands: new roles in immune tolerance and beyond. Nat Rev Immunol. 2016;16:247–258.
[7] Ponranjini V, Bakyalakshmi K, Jayachandran S, et al. Autoimmune polyglandular syndrome type 1. J Clin Imaging Sci. 2012;2:62.
[8] Michels AW, Gottlieb PA. Autoimmune polyglandular syndromes. Nat Rev Endocrinol. 2010;6:270–277.
[9] Koo S, Kejariwal D, Al-Shehri T, et al. Oesophageal candidiasis and squamous cell cancer in patients with gain-of-function STAT1 gene mutation. United Eur Gastroenterol J. 2017;5:625–631.
[10] Hernández-Santos N, Gaffen SL. Th17 cells in immunity to Candida albicans. Cell Host Microbe. 2012;11:425–435.
[11] Białkowska J, Zygmunt A, Lewiński A, et al. Hepatitis and the polyglandular autoimmune syndrome, type 1. Arch Med Sci. 2011;7:536–539.
[12] Sorkina E, Frolova E, Rusinova D, et al. Progressive generalized lipodystrophy as a manifestation of autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab. 2016;101:1344–1347.
[13] Kahaly GJ. Genetics of polyglandular failure. Genet Diagnosis Endocr Disord. 2016;361–373. DOI:10.1016/B978-0-12-80892-8.00025-7
[14] Guttmann-Bauman I, Shi J-D, Wang C-Y, et al. Detection of AIRE mutation in atypical Autoimmune Polyglandular Syndrome Type 1 (APS1). Int J Disabil Hum Dev. 2001;2:115.